

Vaccine Fact Sheet MenACWY (MCV4)

Brand Name	Menactra®	Menveo®	MenQuadfi
Manufacturer	Sanofi Pasteur	GlaxoSmithKline (GSK)	Sanofi Pasteur
Abbreviation	MenACWY-D	MenACWY-CRM	MenACWY-TT
Protects Against	Invasive Meningococcal Disease caused by <i>Neisseria meningitidis</i> A, C, Y and W-135	Invasive Meningococcal Disease caused by <i>Neisseria meningitidis</i> A, C, Y and W-135	Invasive Meningococcal Disease caused by <i>Neisseria meningitidis</i> A, C, Y and W-135
Routine Schedule	One (1) dose at 11-12 years and one (1) booster dose at 16 years	One (1) dose at 11-12 years and one (1) booster dose at 16 years	One (1) dose at 11-12 years and one (1) booster dose at 16 years
Minimum Intervals	8 week minimum interval between doses	8 week minimum interval between doses	4 years minimum interval between doses
Approved for use in	Persons aged 9 months through 55 years	Persons aged 2 months through 55 years	Persons aged 2 years and older
Administration	Intramuscular (IM) injection	Intramuscular (IM) injection	Intramuscular (IM) injection
Packaging	Vaccine is packaged as 5 single-dose 0.5mL vials	Vaccine is packaged as 5 single-dose 0.5mL vials of Men CYW-135 liquid component and 5 single-dose vials of lyophilized Men A component.	Vaccine is packaged as 5 single-dose 0.5mL vials
Storage	Refrigerate between 36°F and 46°F (2°C to 8°C) DO NOT FREEZE	Refrigerate between 36°F and 46°F (2°C to 8°C) PROTECT VACCINE FROM LIGHT DO NOT FREEZE	Refrigerate between 36°F to 46°F (2°C to 8°C). DO NOT FREEZE
Full ACIP Recommendations	https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html	https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html	https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html
VFC Letter	http://eziz.org/assets/docs/vfcletter_2011_11_MCV4.pdf	http://eziz.org/assets/docs/vfcletter_2011_11_MCV4.pdf	https://eziz.org/assets/docs/VFC_Letters/2021/July8 MenQuadfi.pdf
Billing Codes*	CHDP code: 69 CPT code for vaccine: 90734 CPT code for administration: 90460 Medi-Cal Fee-For-Service (FFS) administration: 90734 with modifiers –SK (high-risk) and –SL (VFC) ICD-10-CM code (encounter for immunization): Z23 * https://www.aafp.org/family-physician/practice-and-career/getting-paid/coding/vaccine-administration.html	CHDP code: 69 CPT code for vaccine: 90734 CPT code for administration: 90460 Medi-Cal Fee-For-Service (FFS) administration: 90734 with modifiers –SK (high-risk) and –SL (VFC) ICD-10-CM code (encounter for immunization): Z23 * https://www.aafp.org/family-physician/practice-and-career/getting-paid/coding/vaccine-administration.html	CHDP code: 69 CPT code for vaccine: 90619 CPT code for administration: 90460 Medi-Cal Fee-For-Service (FFS) administration: 90619 with modifiers –SK (high-risk) and –SL (VFC) NDC code: 49281-590-05 ICD-10-CM code (encounter for immunization): Z23 * https://www.aafp.org/family-physician/practice-and-career/getting-paid/coding/vaccine-administration.html



Vaccine Fact Sheet MenACWY (MCV4)

Brand Name
Manufacturer
Abbreviation

Menactra®
Sanofi Pasteur
MenACWY-D

Menveo®
GlaxoSmithKline (GSK)
MenACWY-CRM

MenQuadfi™
Sanofi Pasteur
MenACWY-TT

Comments

- Licensed in 2005
- Boosters are recommended for those who remain at high risk. See ACIP recommendations.
- Does not protect against Meningococcal serogroup B
- For routine recommendations, refer to [Meningococcal Vaccines—Routine Risk](#)
- For recommendations for high-risk patients, refer to [Meningococcal Vaccines—High Risk Populations](#)
If Menactra is given to children with HIV infection or asplenia (including sickle cell disease), wait at least age 2 years before giving Menactra and it should not be administered until at least 4 weeks after completion of all PCV13 doses. See ACIP recommendations. These restrictions do not apply to Menveo or MenQuadfi.
- It is recommended that Menactra be given either before, or concomitantly with, the next recommended dose of DTaP vaccine.

- Licensed in 2010
- Boosters are recommended for those who remain at high risk. See ACIP recommendations. Does not protect against Meningococcal serogroup B
- For routine recommendations, refer to [Meningococcal Vaccines—Routine Risk](#)
For recommendations for high-risk patients, refer to [Meningococcal Vaccines—High Risk Populations](#)
- Use only supplied (CWY) liquid component to reconstitute freeze dried component (A)
- MenCWY and Men A vials have separate lot numbers; record the lot numbers from the box

- Licensed in 2020
- Boosters are recommended for those who remain at high risk. See ACIP recommendations.
- Does not protect against Meningococcal serogroup B
- For routine recommendations, refer to [Meningococcal Vaccines—Routine Risk](#)
- For recommendations for high-risk patients, refer to [Meningococcal Vaccines—High Risk Populations](#)
- MenACWY-TT, which is conjugated to tetanus toxoid, is only licensed for the prevention of meningococcal disease; use of this vaccine does not replace doses or affect the dosing intervals of routinely recommended tetanus toxoid-containing vaccines in any age group. See ACIP recommendations.